Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cellsThe authors declare no competing interests

Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its...

Full description

Saved in:
Bibliographic Details
Main Authors: Luo, Lian-Xiang, Fan, Xing-Xing, Li, Ying, Peng, Xia, Ji, Yin-Chun, Hsiao, Wendy Wen-Luan, Liu, Liang, Leung, Elaine Lai-Han, Yao, Xiao-Jun
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis. We reported that mitoxantrone, an FDA approved drug for anti-cancer chemotherapy drugs, is a direct potent inhibitor of ROS1 kinase.
ISSN:2040-2503
2040-2511
DOI:10.1039/c6md00643d